|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: GLOBOCAN 2008 v2.0, Cancer Incidence and
Mortality Worldwide: IARC CancerBase No. 10 (Internet).
International Agency for Research on Cancer; Lyon: 2010, http://globocan.iarc.fr.
access date: 11/06/2013
|
|
2
|
Moghimi-Dehkordi B and Safaee A: An
overview of colorectal cancer survival rates and prognosis in Asia.
World J Gastrointest Oncol. 4:71–75. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sung JJ, Lau JY, Goh KL and Leung WK:
Increasing incidence of colorectal cancer in Asia: implications for
screening. Lancet Oncol. 6:871–876. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ransohoff DF and Sandler RS: Clinical
practice. Screening for colorectal cancer. N Engl J Med. 346:40–44.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Osborn NK and Ahlquist DA: Stool screening
for colorectal cancer: molecular approaches. Gastroenterology.
128:192–206. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Takai T, Kanaoka S, Yoshida K, et al:
Fecal cyclooxygenase 2 plus matrix metalloproteinase 7 mRNA assays
as a marker for colorectal cancer screening. Cancer Epidemiol
Biomarkers Prev. 18:1888–1893. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bartel DP: MicroRNAs: genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hwang HW and Mendell JT: MicroRNAs in cell
proliferation, cell death, and tumorigenesis. Br J Cancer.
94:776–780. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kong YW, Ferland-McCollough D, Jackson TJ
and Bushell M: microRNAs in cancer management. Lancet Oncol.
13:e249–e258. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Esquela-Kerscher A and Slack FJ: Oncomirs
- microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006.
View Article : Google Scholar
|
|
12
|
Motoyama K, Inoue H, Takatsuno Y, et al:
Over- and under-expressed microRNAs in human colorectal cancer. Int
J Oncol. 34:1069–1075. 2009.PubMed/NCBI
|
|
13
|
Bandres E, Cubedo E, Agirre X, et al:
Identification by Real-time PCR of 13 mature microRNAs
differentially expressed in colorectal cancer and non-tumoral
tissues. Mol Cancer. 5:292006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang CJ, Zhou ZG, Wang L, et al:
Clinicopathological significance of microRNA-31, -143 and -145
expression in colorectal cancer. Dis Markers. 26:27–34. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen Y, Song Y, Wang Z, et al: Altered
expression of miR-148a and miR-152 in gastrointestinal cancers and
its clinical significance. J Gastrointest Surg. 14:1170–1179. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Slaby O, Svoboda M, Fabian P, et al:
Altered expression of miR-21, miR-31, miR-143 and miR-145 is
related to clinicopathologic features of colorectal cancer.
Oncology. 72:397–402. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hamfjord J, Stangeland AM, Hughes T, et
al: Differential expression of miRNAs in colorectal cancer:
comparison of paired tumor tissue and adjacent normal mucosa using
high-throughput sequencing. PLoS One. 7:e341502012. View Article : Google Scholar
|
|
18
|
Faltejskova P, Svoboda M, Srutova K, et
al: Identification and functional screening of microRNAs highly
deregulated in colorectal cancer. J Cell Mol Med. 16:2655–2666.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xu XM, Qian JC, Deng ZL, et al: Expression
of miR-21, miR-31, miR-96 and miR-135b is correlated with the
clinical parameters of colorectal cancer. Oncol Lett. 4:339–345.
2012.PubMed/NCBI
|
|
20
|
Mazeh H, Mizrahi I, Ilyayev N, et al: The
diagnostic and prognostic role of microRNA in colorectal cancer - a
comprehensive review. J Cancer. 4:281–295. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ahmed FE, Jeffries CD, Vos PW, et al:
Diagnostic microRNA markers for screening sporadic human colon
cancer and active ulcerative colitis in stool and tissue. Cancer
Genomics Proteomics. 6:281–295. 2009.
|
|
22
|
Koga Y, Yasunaga M, Takahashi A, et al:
MicroRNA expression profiling of exfoliated colonocytes isolated
from feces for colorectal cancer screening. Cancer Prev Res
(Phila). 3:1435–1442. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Link A, Balaguer F, Shen Y, et al: Fecal
microRNAs as novel biomarkers for colon cancer screening. Cancer
Epidemiol Biomarkers Prev. 19:1766–1774. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wu CW, Ng SS, Dong YJ, et al: Detection of
miR-92a and miR-21 in stool samples as potential screening
biomarkers for colorectal cancer and polyps. Gut. 61:739–745.
2011.PubMed/NCBI
|
|
25
|
Yamazaki N, Koga Y, Yamamoto S, et al:
Application of the fecal microRNA test to the residuum from the
fecal occult blood test. Jpn J Clin Oncol. 43:726–733. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li JM, Zhao RH, Li ST, et al:
Down-regulation of fecal miR-143 and miR-145 as potential markers
for colorectal cancer. Saudi Med J. 33:24–29. 2012.PubMed/NCBI
|
|
27
|
Kalimutho M, Del Vecchio Blanco G, Di
Cecilia S, et al: Differential expression of miR-144* as a novel
fecal-based diagnostic marker for colorectal cancer. J
Gastroenterol. 46:1391–1402. 2011.
|
|
28
|
Ahmed FE, Ahmed NC, Vos PW, et al:
Diagnostic microRNA markers to screen for sporadic human colon
cancer in stool: I. Proof of principle. Cancer Genomics Proteomics.
10:93–113. 2013.PubMed/NCBI
|
|
29
|
Mao X, Yu Y, Boyd LK, et al: Distinct
genomic alterations in prostate cancers in Chinese and Western
populations suggest alternative pathways of prostate
carcinogenesis. Cancer Res. 70:5207–5212. 2010. View Article : Google Scholar
|
|
30
|
Pritchard CC, Kroh E, Wood B, et al: Blood
cell origin of circulating microRNAs: a cautionary note for cancer
biomarker studies. Cancer Prev Res (Phila). 5:492–497. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kirschner MB, Kao SC, Edelman JJ, et al:
Haemolysis during sample preparation alters microRNA content of
plasma. PLoS One. 6:e241452011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Vandesompele J, De Preter K, Pattyn F, et
al: Accurate normalization of real-time quantitative RT-PCR data by
geometric averaging of multiple internal control genes. Genome
Biol. 3:RESEARCH00342002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Slaby O, Svoboda M, Michalek J and Vyzula
R: MicroRNAs in colorectal cancer: translation of molecular biology
into clinical application. Mol Cancer. 8:1022009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sun J, Chen Z, Tan X, et al:
MicroRNA-99a/100 promotes apoptosis by targeting mTOR in human
esophageal squamous cell carcinoma. Med Oncol. 30:4112013.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Torres A, Torres K, Pesci A, et al:
Deregulation of miR-100, miR-99a and miR-199b in tissues and plasma
coexists with increased expression of mTOR kinase in endometrioid
endometrial carcinoma. BMC Cancer. 12:3692012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chen Z, Jin Y, Yu D, et al:
Down-regulation of the microRNA-99 family members in head and neck
squamous cell carcinoma. Oral Oncol. 48:686–691. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Huang ZM, Yang J, Shen XY, et al: MicroRNA
expression profile in non-cancerous colonic tissue associated with
lymph node metastasis of colon cancer. J Dig Dis. 10:188–194. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Li X, Zhang Y, Zhang H, et al: miRNA-223
promotes gastric cancer invasion and metastasis by targeting tumor
suppressor EPB41L3. Mol Cancer Res. 824–833. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Li S, Li Z, Guo F, et al: miR-223
regulates migration and invasion by targeting Artemin in human
esophageal carcinoma. J Biomed Sci. 18:242011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wu L, Li H, Jia CY, et al: MicroRNA-223
regulates FOXO1 expression and cell proliferation. FEBS Lett.
586:1038–1043. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Godlewski J, Bronisz A, Nowicki MO,
Chiocca EA and Lawler S: microRNA-451: a conditional switch
controlling glioma cell proliferation and migration. Cell Cycle.
9:2742–2748. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Godlewski J, Nowicki MO, Bronisz A, et al:
MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to
metabolic stress in glioma cells. Mol Cell. 37:620–632. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wang T, Zang WQ, Li M, Wang N, Zheng YL
and Zhao GQ: Effect of miR-451 on the biological behavior of the
esophageal carcinoma cell line EC9706. Digest Dis Sci. 58:706–714.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Molinari F, Felicioni L, Buscarino M, et
al: Increased detection sensitivity for KRAS mutations
enhances the prediction of anti-EGFR monoclonal antibody resistance
in metastatic colorectal cancer. Clin Cancer Res. 17:4901–4914.
2011.PubMed/NCBI
|
|
45
|
Bandres E, Bitarte N, Arias F, et al:
microRNA-451 regulates macrophage migration inhibitory factor
production and proliferation of gastrointestinal cancer cells. Clin
Cancer Res. 15:2281–2290. 2009. View Article : Google Scholar : PubMed/NCBI
|
